By SPC News Staff
Secukinumab (Cosentyx, Novartis) improved skin symptoms and quality of life (QOL) for up to 52 weeks in children and adolescents 6 to 17 years of age with moderate to severe plaque psoriasis, according to two studies presented at the 2021 American Academy of Dermatology Virtual Meeting Experience (AAD VMX).
The first study was a multicenter, double-blind study that looked at 162 children with severe plaque psoriasis who received either a low dose (LD; 75-50 mg) or high